Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Depressive Disorder, Major

In brief

A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.

Key facts

Study ID

NCT00143091

Run by

Pfizer

People needed

200

Starts

2005-04-01

Expected to finish

2006-04-01

Last updated by the study team

2008-03-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients with DSM-IV major depressive disorder

You may not qualify if…

• Women of child bearing potential

Where it is running

• Pfizer Investigational Site — Bellevue, Washington, United States
• Pfizer Investigational Site — Seattle, Washington, United States
• Pfizer Investigational Site — Moscow, Russia
• Pfizer Investigational Site — Rostov-on-Don, Russia
• Pfizer Investigational Site — Saint Petersburg, Russia
• Pfizer Investigational Site — Smolensk, Russia
• Pfizer Investigational Site — Belgrade, Serbia, Serbia and Montenegro
• Pfizer Investigational Site — Kragujevac, Serbia, Serbia and Montenegro
• Pfizer Investigational Site — Novi Sad, Serbia, Serbia and Montenegro
• Pfizer Investigational Site — Belgrade, Serbia and Montenegro

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.